(Reuters) – Eagle Pharmaceuticals Inc said on Wednesday the U.S. Food and Drug Administration approved its generic version of Vasostrict, a blood pressure drug developed by Endo International’s subsidiary Par Pharmaceutical Inc.
In August, a Delaware federal court had ruled that Eagle’s proposed generic of Par Pharmaceutical’s best-selling drug did not infringe Par’s patents.
(Reporting by Dania Nadeem in Bengaluru; Editing by Ramakrishnan M.)
